GL1X · GenesisL1 explorer

MolNFT v1 · #134245 · protein

Circularly permutated azurin (cpaz) based on P. aeruginosa azurin sequence

5SYD · Azurin, chimeric construct: “Circularly permutated azurin (cpaz) based on P. aeruginosa azurin sequence”. X-ray diffraction, 1 ligand (CU), 2 pockets (best druggability 0.46). MolNFT v1 #134245 on GenesisL1: 3D structure, binding…

PDB
5SYD
Type
protein
Length
261 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Azurin, chimeric construct
UniProt
P00282, B3EWN9
Ligands
CU
Pockets
2 · best druggability 0.46

Structure

x-ray diffraction · 2 distinct chains · 15% helix, 34% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAzurin, chimeric constructprotein13015% helix, 35% strandP00282, B3EWN9
BAzurin, chimeric constructprotein13115% helix, 33% strandP00282, B3EWN9

Ligands and binding sites

  • CU · Copper (II) ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11040.460.7921empty
2660.330.7616empty

Interfaces

1 interface between chains.

  • A–B · 426 Ų buried · 1 hydrogen bond · protein-protein

Modifications

Observed in the structure: 2 disulfide (disulfide).

Compared structures

  • 5SYD · Circularly permutated azurin (cpAz) based on P. aeruginosa azurin sequence · the same entry in another collection · chain A against A, TM-score 1.00
  • B3EWN9 · AlphaFold monomer V2.0 prediction for azurin (B3EWN9) · a predicted model of the same protein · chain B against A, TM-score 0.66
  • P00282 · AlphaFold monomer V2.0 prediction for azurin (P00282) · a predicted model of the same protein · chain B against A, TM-score 0.66

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.